MBX Biosciences, Inc. Share Price
MBXMBX Biosciences, Inc. Stock Performance
Open $28.66 | Prev. Close $32.06 | Circuit Range N/A |
Day Range $28.63 - $32.90 | Year Range $4.81 - $34.71 | Volume 1,16,564 |
Average Traded $31.41 |
MBX Biosciences, Inc. Share Price Chart
About MBX Biosciences, Inc.
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
MBX Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
04-Dec-25 | $28.66 | $30.52 | +0.00% |
04-Dec-25 | $28.66 | $30.52 | -9.93% |
03-Dec-25 | $34.06 | $33.89 | +2.39% |
02-Dec-25 | $33.26 | $33.10 | +0.33% |
01-Dec-25 | $34.04 | $32.99 | -4.32% |
28-Nov-25 | $34.06 | $34.48 | +2.15% |
26-Nov-25 | $31.89 | $33.76 | +6.82% |